Sign inJoin waitlistJoin the waitlist

Komal Akhtar

Physician · Auburn Community Hospital

Credentials: · · · ·

History

Auburn Community Hospital
2022–Present

Hematology and Medical Oncology
SUNY Upstate Medical University
2018–2021
Internal Medicine
SUNY Upstate Medical University
2015–2018
Saint George's University School of Medicine
2011–2015

Research

A Rare Case of Aggressive Atypical Cervical Cancer With Multi-Organ Involvement
Case report · Cureus · 2022 · Last of 8 authors · 6 citations
Small Cell Neuroendocrine of the Head and Neck: A Rare Presentation and Review of the Literature
Case report · Journal of Investigative Medicine High Impact Case Reports · 2022 · Last of 6 authors · 5 citations
Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
Case report · Journal of Investigative Medicine High Impact Case Reports · 2022 · First of 4 authors · 4 citations

MS
Michael Sandhu
4 papers · 4 as a resident
Alanna Siegenthaler
3 papers
Stephanie Niforatos
3 papers
Adam Zayac
2 papers · 2 as a fellow
CT
Che-Kai Tsao
2 papers
MS
Metlapalli Venkata Sravanthi
2 papers · 2 as a fellow
PK
Prashanth Ashok Kumar
2 papers · 2 as a fellow
Susu Zhou
2 papers
Taylor Loon
2 papers · 2 as a resident
Vishw Patel
2 papers · 2 as a resident
Abirami Sivapiragasam
1 paper
AB
Alina Basnet
1 paper

Clinical trials

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2026
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027